Skip to main navigation Skip to search Skip to main content

Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma

  • Anne von Mässenhausen
  • , Mario Deng
  • , Hannah Billig
  • , Angela Queisser
  • , Wenzel Vogel
  • , Glen Kristiansen
  • , Andreas Schröck
  • , Friedrich Bootz
  • , Friederike Göke
  • , Alina Franzen
  • , Lynn Heasley
  • , Jutta Kirfel
  • , Johannes Brägelmann
  • , Sven Perner*
  • *Corresponding author for this work
  • University of Bonn
  • Airway Research Center North
  • University of Colorado

Abstract

Background: Although head and neck squamous cell carcinoma (HNSCC) is the sixth most common tumour entity worldwide, it remains a clinical challenge. Large-scale explorative genomic projects have identified several genes as potential targets for therapy, including fibroblast growth factor receptor 3 (FGFR3). Aims: The aim of this study was to investigate the biological significance of wild-type and mutated FGFR3 to evaluate its potential as a novel therapeutic target in HNSCC. Methods: FGFR3 protein expression was analysed in a large HNSCC tissue cohort (n = 536) and FGFR3 mRNA expression from The Cancer Genome Atlas (TCGA; n = 520). Moreover, FGFR3 wild-type and mutant versions were overexpressed in vitro, and both proliferation and migration was assessed with and without BGJ398 (a specific FGFR1-3 inhibitor) treatment. Results: Although FGFR3 expression for both cohorts decreased during tumour progression, high FGFR3 expression levels were observed in a small subset of patients. In vitro, FGFR3 overexpression led to increased proliferation, whereas migration was not altered. Moreover, FGFR3-overexpressing cells were more sensitive to BGJ398. Cells overexpressing FGFR3 mutant versions showed increased proliferation compared to wild-type FGFR3 under serum-reduced conditions and were largely as sensitive as the wild-type protein to BGJ398. Conclusions: Taken together, the results of this study demonstrate that although FGFR3 expression decreases during HNSSC progression, it plays an important role in tumour cell proliferation and thus may be a potential target for therapy in selected patients suffering from this dismal tumour entity. [Figure not available: see fulltext.]

Original languageEnglish
JournalTargeted Oncology
Volume11
Issue number5
Pages (from-to)631-642
Number of pages12
ISSN1776-2596
DOIs
Publication statusPublished - 01.10.2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma'. Together they form a unique fingerprint.

Cite this